TY - JOUR
T1 - Phage display for identification of serum biomarkers of traumatic brain injury
AU - Ghoshal, Sarbani
AU - Bondada, Vimala
AU - Saatman, Kathryn E.
AU - Guttmann, Rodney P.
AU - Geddes, James W.
N1 - Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/10/15
Y1 - 2016/10/15
N2 - Background The extent and severity of traumatic brain injuries (TBIs) can be difficult to determine with current diagnostic methods. To address this, there has been increased interest in developing biomarkers to assist in the diagnosis, determination of injury severity, evaluation of recovery and therapeutic efficacy, and prediction of outcomes. Several promising serum TBI biomarkers have been identified using hypothesis-driven approaches, largely examining proteins that are abundant in neurons and non-neural cells in the CNS. New method An unbiased approach, phage display, was used to identify serum TBI biomarkers. In this proof-of-concept study, mice received a TBI using the controlled cortical impact model of TBI (1 mm injury depth, 3.5 m/s velocity) and phage display was utilized to identify putative serum biomarkers at 6 h postinjury. Results An engineered phage which preferentially bound to injured serum was sequenced to identify the 12-mer ‘recognizer’ peptide expressed on the coat protein. Following synthesis of the recognizer peptide, pull down, and mass spectrometry analysis, the target protein was identified as glial fibrillary acidic protein (GFAP). Comparison with existing methods and conclusions GFAP has previously been identified as a promising TBI biomarker. The results provide proof of concept regarding the ability of phage display to identify TBI serum biomarkers. This methodology is currently being applied to serum biomarkers of mild TBI.
AB - Background The extent and severity of traumatic brain injuries (TBIs) can be difficult to determine with current diagnostic methods. To address this, there has been increased interest in developing biomarkers to assist in the diagnosis, determination of injury severity, evaluation of recovery and therapeutic efficacy, and prediction of outcomes. Several promising serum TBI biomarkers have been identified using hypothesis-driven approaches, largely examining proteins that are abundant in neurons and non-neural cells in the CNS. New method An unbiased approach, phage display, was used to identify serum TBI biomarkers. In this proof-of-concept study, mice received a TBI using the controlled cortical impact model of TBI (1 mm injury depth, 3.5 m/s velocity) and phage display was utilized to identify putative serum biomarkers at 6 h postinjury. Results An engineered phage which preferentially bound to injured serum was sequenced to identify the 12-mer ‘recognizer’ peptide expressed on the coat protein. Following synthesis of the recognizer peptide, pull down, and mass spectrometry analysis, the target protein was identified as glial fibrillary acidic protein (GFAP). Comparison with existing methods and conclusions GFAP has previously been identified as a promising TBI biomarker. The results provide proof of concept regarding the ability of phage display to identify TBI serum biomarkers. This methodology is currently being applied to serum biomarkers of mild TBI.
KW - Animal models
KW - Biomarkers
KW - Blood
KW - Concussion
KW - Rodents
KW - Traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=84966713786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84966713786&partnerID=8YFLogxK
U2 - 10.1016/j.jneumeth.2016.04.026
DO - 10.1016/j.jneumeth.2016.04.026
M3 - Article
C2 - 27168498
AN - SCOPUS:84966713786
SN - 0165-0270
VL - 272
SP - 33
EP - 37
JO - Journal of Neuroscience Methods
JF - Journal of Neuroscience Methods
ER -